Clinical Trial Update: Long Term Extension Trial of Setmelanotide [Phase 2, Phase 3]

View source ↗

Summary

This update summarizes the completion of a long-term extension trial evaluating setmelanotide in obesity due to defects in the leptin-melanocortin pathway, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity Due to Defects in the Leptin-melanocortin Pathway

Drugs mentioned

• IMCIVREE (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-05-31